Top Markets
#1 Ontology Gas Ontology Gas +26.62%
#2 EXOD EXOD +22.08%
#3 Status Status +17.01%
#4 Derive Derive +8.72%
#5 Gas Gas +7.44%
#6 Fake World Assets Fake World Assets +6.08%
#7 aelf aelf +5.83%
#8 Tornado Cash Tornado Cash +5.44%
#9 B3 (Base) B3 (Base) +5.37%
#10 DeFi Kingdoms DeFi Kingdoms +5.13%
Coin of the day
Ontology Gas Ontology Gas
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
LianBio LianBio

LianBio

LIAN
Classifica tra le azioni #25845
LianBio is a biopharmaceutical firm dedicated to advancing and commercializing... LianBio is a biopharmaceutical firm dedicated to advancing and commercializing medical treatments for a broad spectrum of conditions, encompassing cardiovascular, oncological, respiratory, ophthalmic, and inflammatory diseases. Its primary operational focus is in China and other Asian nations. The company's development pipeline features several investigational therapies: mavacamten, aimed at addressing obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction; TP-03, for the treatment of Demodex blepharitis; NBTXR3, targeting head and neck squamous cell carcinoma and other solid tumors; Infigratinib, for first-line and second-line cholangiocarcinoma and gastric cancers; BBP-398, also for solid tumors; Omilancor and NX-13, both indicated for ulcerative colitis (with Omilancor additionally for Crohn's disease); LYR-210, for chronic rhinosinusitis; and Sisunatovir, under investigation for respiratory syncytial virus. To further its drug candidates, LianBio has established strategic alliances, including a collaboration with Tarsus Pharmaceuticals, Inc. for the development and commercialization of TP-03, an eye solution for Demodex blepharitis. They also partner with Nanobiotix S.A. for NBTXR3, a radioenhancer designed to be directly administered into malignant tumors before standard radiation therapy. The company was founded in 2019 and is headquartered in Princeton, New Jersey.
Prezzo delle azioni
$0.42275
Ultima sincronizzazione: 2025-07-14
Capitalizzazione di mercato
$45.81M
Variazione (1 giorno)
-0.89%
Variazione (1 anno)
0.00%
Paese
US
Scambia LianBio (LIAN)

Categoria

Healthcare
Storico dividendi per LianBio (LIAN)
LianBio (simbolo azionario: LIAN) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per LianBio (LIAN) dal 2026 al 2026
Pagamenti annuali dei dividendi
Anno Dividendo (rettificato per split azionari) Cambia
Non abbastanza dati per le date fornite.
Elenco di tutti i pagamenti di dividendi
Anno Dividendo Cambia
Non abbastanza dati per le date fornite.
Dividendi di aziende simili o concorrenti
Azienda Numero di pagamenti di dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US